Lumida
/AVTX
⌘K
AVTX

AVTX

AVTX
$19.37USD↑+8.33%+1.49 today

MARKET CAP

1.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$18 – $19

52W RANGE

$5
$24

AI Summary

Stalk
Buy NowMedium

AVTX remains in a Stage 2 advance within a longer-term downtrend. A recent momentum breakout above prior resistance confirms continuation, and rising EMAs with supportive volume validate further upside. As a speculative theme, this clear asymmetric setup warrants a Buy Now at the breakout zone, while monitoring for momentum exhaustion and potential flattening of short EMAs.

  • ↑Phase 2 hidradenitis trial showed significant improvement metrics vs. baseline.
  • ↑Analyst estimate upgrades reflect strong growth outlook.
  • ↓Negative profitability trends raise doubts about cash-flow breakeven.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Avalon Therapeutics (NASDAQ: AVTX) is a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for rare and underserved medical needs. Currently, the company is engaged in advanced clinical trials targeting hidradenitis suppurativa, showcasing its commitment to bringing innovative therapies to market. Positioned within the healthcare sector, Avalo Therapeutics represents a part of the broader theme regarding advancements in biopharmaceuticals, particularly in developing effective treatments for chronic conditions.

Bull says

  • ↑Phase 2 hidradenitis trial showed significant improvement metrics vs. baseline.
  • ↑Analyst estimate upgrades reflect strong growth outlook.
  • ↑High institutional ownership underpins trading stability.
  • ↑Positive price momentum evident in recent share performance.
  • ↑Potential Big Pharma collaborations could accelerate commercialization.
  • ↑Strong growth and revision factors highlight investor interest.

Bear says

  • ↓Negative profitability trends raise doubts about cash-flow breakeven.
  • ↓Elevated debt levels heighten financial vulnerability.
  • ↓Low earnings yield suggests limited return potential.
  • ↓Intense biotech competition may limit market penetration.
  • ↓Pipeline setbacks risk worsening market sentiment and funding.
  • ↓Financial strain could delay key R&D milestones.

Investment themes with AVTX

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 07-11-2026neutral

Transcript signals

Bull points

  • Our onboarding yield of 13.8% during the fourth quarter remained near our historic highs, reflecting the ability of our team to source and structure new quality venture loans even in this challenging environment.
  • Our debt portfolio yield of 16.8% for the quarter and 16.6% for the full year was again one of the highest yielding debt portfolios in the BDC industry.
  • We believe our committed backlog, with most of our funding commitments subject to our portfolio companies achieving certain key milestones, provides a solid base as we look forward to prudently grow our portfolio during the course of the year.

Bear points

  • we expect modest prepayments in the first quarter of 2024, with this normal seasonal trend compounded by the weak IPO and M&A markets at the end of 2023 continuing in the first month of 2024.
  • Net investment income for the fourth quarter of 2023 was $0.45 per share compared to $0.53 per share in the third quarter of 2023, and $0.40 per share for the fourth quarter of 2022.
  • The 70-cent reduction on NAV on a quarterly basis was primarily due to paid distributions, including the 5 cents per share special distribution, realized losses, and adjustments to fair value, partially offset by net investment income.
Read full transcript analysis ›